INT119411

Context Info Confidence 0.38 First Reported 2004 Last Reported 2010 Negated 1 Speculated 0 Reported most in Abstract Documents 22 Total Number 22 Disease Relevance 7.84 Pain Relevance 7.63

mitochondrion (Tst) RNA binding (Tst) plasma membrane (Tst)

Anatomy Link Frequency B-cell 1 tail 1 bone marrow 1 body 1 Tst (Mus musculus)

Pain Link Frequency Relevance Heat antidepressant 354 100.00 Eae 178 100.00 antagonist 197 99.26 fluoxetine 26 99.24 depression 131 98.84 Serotonin 78 97.74 agonist 42 96.80 Catecholamine 6 92.32 Hippocampus 79 91.00 sSRI 21 89.76

Disease Link Frequency Relevance Heat Targeted Disruption 38 100.00 Body Weight 2 99.24 Depression 153 98.84 Disease 103 98.28 Lymphatic System Cancer 272 95.08 Depressive Disorder 9 89.24 Stress 23 87.04 Hypothermia 2 85.80 Ocular Toxicity (including Many Sub-types) 2 85.16 Sprains And Strains 291 84.40

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The behavioral phenotype was identified as likely due to a disinhibition of 5-HT release, because depletion of 5-HT with parachlorophenylalanine selectively reduced immobility of female 5-HT1B receptor knockout mice in the TST.

Negative_regulation (reduced) of TST associated with targeted disruption

1) Confidence 0.38 Published 2005 Journal Neuropsychopharmacology Section Abstract Doc Link 15688089 Disease Relevance 0.98 Pain Relevance 0.28

Also, both male and female 5-HT1B receptor knockout mice demonstrated reductions of immobility in the TST after treatment with fluoxetine.

Negative_regulation (reductions) of TST associated with targeted disruption and fluoxetine

2) Confidence 0.38 Published 2005 Journal Neuropsychopharmacology Section Abstract Doc Link 15688089 Disease Relevance 0.98 Pain Relevance 0.33

The immobility time in the TST was significantly reduced by the extract (dose range 30-600 mg/kg, p.o.), without accompanying changes in ambulation when assessed in an open-field test.

Negative_regulation (reduced) of TST

3) Confidence 0.38 Published 2007 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 17182164 Disease Relevance 0.19 Pain Relevance 0.39

The results showed that intra-gastric administration of genipin at 50, 100, 200mg/kg or fluoxetine at 7.5mg/kg for 7 days significantly reduced the duration of immobility in FST and TST, while it did not affect the locomotor activity in the open field test (OFT).

Negative_regulation (reduced) of TST associated with eae and fluoxetine

4) Confidence 0.37 Published 2010 Journal Neurosci. Lett. Section Abstract Doc Link 20561935 Disease Relevance 0.41 Pain Relevance 0.63

The anti-immobility effect of the extract (30 mg/kg, p.o.) in the TST was prevented by pre-treatment of mice with ketanserin (5 mg/kg, i.p., a preferential 5-HT(2A) receptor antagonist), prazosin (1 mg/kg, i.p., an alpha(1)-adrenoceptor antagonist), yohimbine (1 mg/kg, i.p., an alpha(2)-adrenoceptor antagonist), propranolol (2 mg/kg, i.p., a beta-adrenoceptor antagonist), sulpiride (50 mg/kg, i.p., a dopamine D(2) receptor antagonist) and SCH23390 (0.05 mg/kg, s.c., a dopamine D(1) receptor antagonist).

Negative_regulation (prevented) of TST associated with dopamine and antagonist

5) Confidence 0.37 Published 2010 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 20026371 Disease Relevance 0.08 Pain Relevance 0.79

Second, antidepressant treatment reduces immobility in the TST and FST, while antipsychotic treatment has no effect (Crowley et al. 2004).

Negative_regulation (reduces) of TST associated with antidepressant

6) Confidence 0.36 Published 2010 Journal Mamm Genome Section Body Doc Link PMC2890984 Disease Relevance 0.80 Pain Relevance 0.29

The dose of 150 mg/kg of the extract significantly reduced the immobility times of mice in both FST and TST, without any significant effect on locomotor activity of mice.

Negative_regulation (reduced) of TST associated with eae

7) Confidence 0.33 Published 2006 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 16443316 Disease Relevance 0.09 Pain Relevance 0.55

At doses of 150 and 300 mg/kg body weight, p.o., the BFM extract significantly reduced the total duration of immobility in the TST, while individual differences in locomotor activities between experimental groups were not observed in the OFT.

Negative_regulation (reduced) of TST in body associated with body weight and eae

8) Confidence 0.33 Published 2010 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 19932727 Disease Relevance 0.17 Pain Relevance 0.56

The aim of the present study was to explore further the antidepressant-like properties of the NOP antagonist UFP-101 in different species (mouse and rat) and using different assays [FST and tail suspension test (TST)], and to investigate the mechanism(s) involved in its actions.UFP-101 (10 nmol i.c.v.) reduced immobility time of Swiss mice in the TST (mean+/-SEM) from 179+/-11 to 111+/-10 s.

Negative_regulation (reduced) of TST in tail associated with antidepressant and antagonist

9) Confidence 0.31 Published 2004 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 15197534 Disease Relevance 0.08 Pain Relevance 0.47

At the lower dose, SB-205384 significantly (p < 0.0001) reduced TST immobility in B6 (n = 14) but not in NZB (n = 9) mice compared to vehicle-treated mice (B6, n = 12; NZB, n = 9) (Fig. 5a).

Neg (not) Negative_regulation (reduced) of TST

10) Confidence 0.30 Published 2010 Journal Mamm Genome Section Body Doc Link PMC2890984 Disease Relevance 0.38 Pain Relevance 0.25

SB-205384 significantly reduced TST immobility in B6 mice without affecting general activity, but it had no effect on behavior in NZB mice.

Negative_regulation (reduced) of TST

11) Confidence 0.30 Published 2010 Journal Mamm Genome Section Abstract Doc Link PMC2890984 Disease Relevance 0.43 Pain Relevance 0.16

First, clinically effective human treatments such as antidepressants reduce TST and FST immobility [9], [10]; second, manipulation of genes known to be involved in depression in humans affects TST and FST performance [11], [12], [13], [14]; and, finally, mice bred to express a behavioral or physiological “depressive” phenotype show increased immobility [15], [16], [17].

Negative_regulation (reduce) of TST associated with antidepressant and depression

12) Confidence 0.29 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012073 Disease Relevance 0.89 Pain Relevance 0.18

Some studies excluded patients who had disease that progressed in field within a year after 35 Gy EBRT.13,19,20 Treatment with dose attenuated 131I-TST in patients with greater than 25% bone marrow involvement has been reported and remains investigational.21 Dosing and treatment delivery

Negative_regulation (attenuated) of 131I-TST in bone marrow associated with disease

13) Confidence 0.28 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.70 Pain Relevance 0

One might consider the effectiveness of 131I-TST after previous treatment with 131I-TST.

Negative_regulation (effectiveness) of 131I-TST

14) Confidence 0.28 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.32 Pain Relevance 0

For patients who have received prior ASCT, dose-reduced 131I-TST is a viable option with a chance for response and even long-term control. 131I-TST in the frontline management of B-cell NHL

Negative_regulation (reduced) of 131I-TST in B-cell associated with lymphatic system cancer

15) Confidence 0.28 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.73 Pain Relevance 0

With such impressive preclinical data for some monoclonal antibodies, one wonders about the effectiveness of TST without 131I labeling.

Negative_regulation (effectiveness) of TST

16) Confidence 0.28 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.21 Pain Relevance 0

A single i.c.v. administration of alpha-tocopheryl phosphate, a water-soluble analogue of alpha-tocopherol, also reduced the immobility time in the FST (0.1 and 1 nmol/site) and in the TST (0.1 nmol/site).

Negative_regulation (reduced) of TST associated with eae

17) Confidence 0.27 Published 2010 Journal Behav. Brain Res. Section Abstract Doc Link 20144659 Disease Relevance 0.07 Pain Relevance 0.50

The acute oral treatment with alpha-tocopherol at the doses of 30 and 100mg/kg reduced the immobility time in the FST and in the TST.

Negative_regulation (reduced) of TST associated with eae

18) Confidence 0.27 Published 2010 Journal Behav. Brain Res. Section Abstract Doc Link 20144659 Disease Relevance 0.07 Pain Relevance 0.44

In B6 mice, a low dose of SB-205384 decreased TST immobility without affecting either general locomotor activity or OFT center preference.

Negative_regulation (decreased) of TST associated with eae

19) Confidence 0.27 Published 2010 Journal Mamm Genome Section Body Doc Link PMC2890984 Disease Relevance 0.25 Pain Relevance 0.29

The results have clearly shown that citalopram and fluoxetine were not active in the serotonin-depleted mice, while in control groups of animals (not treated with PCPA), both compounds induced a significant decrease in the immobility time in the TST.

Negative_regulation (decrease) of TST associated with serotonin and fluoxetine

20) Confidence 0.19 Published 2010 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2981731 Disease Relevance 0 Pain Relevance 0.62

General Comments

This test has worked.